A
Aaron E. Miller
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 74
Citations - 7992
Aaron E. Miller is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Teriflunomide & Multiple sclerosis. The author has an hindex of 27, co-authored 67 publications receiving 6802 citations. Previous affiliations of Aaron E. Miller include Maimonides Medical Center & University of Ottawa.
Papers
More filters
Journal ArticleDOI
Defining the clinical course of multiple sclerosis: The 2013 revisions
Fred D. Lublin,Stephen C. Reingold,Jeffrey A. Cohen,Gary Cutter,Per Soelberg Sørensen,Alan J. Thompson,Jerry S. Wolinsky,Laura J. Balcer,Brenda Banwell,Frederik Barkhof,Bruce F. Bebo,Peter A. Calabresi,Michel Clanet,Giancarlo Comi,Robert J. Fox,Mark S. Freedman,Andrew D. Goodman,Matilde Inglese,Ludwig Kappos,Bernd C. Kieseier,John A. Lincoln,Catherine Lubetzki,Aaron E. Miller,Xavier Montalban,Paul O'Connor,John Petkau,Carlo Pozzilli,Richard A. Rudick,Maria Pia Sormani,Olaf Stüve,Emmanuelle Waubant,Chris H. Polman +31 more
TL;DR: Refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression are proposed and strategies for future research to better define phenotypes are outlined.
Journal ArticleDOI
Development of a multiple sclerosis functional composite as a clinical trial outcome measure
Gary Cutter,Monika Baier,Richard A. Rudick,Diane Cookfair,J. S. Fischer,John Petkau,Karl Syndulko,Brian G. Weinshenker,Jack P. Antel,Christian Confavreux,George W. Ellison,Fred D. Lublin,Aaron E. Miller,Stephen M. Rao,Stephen C. Reingold,Alan J. Thompson,Ernest Willoughby +16 more
TL;DR: A composite measure encompassing the major clinical dimensions of arm, leg and cognitive function was identified and termed the multiple sclerosis functional composite (MSFC), suggesting that the MSFC is more sensitive to change than the EDSS.
Journal ArticleDOI
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
Paul O'Connor,Jerry S. Wolinsky,Christian Confavreux,Giancarlo Comi,Ludwig Kappos,Tomas Olsson,Hadj Benzerdjeb,Philippe Truffinet,Lin Wang,Aaron E. Miller,Mark S. Freedman +10 more
TL;DR: Teriflunomide significantly reduced relapse rates, disability progression (at the higher dose), and MRI evidence of disease activity, as compared with placebo.
Journal ArticleDOI
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Christian Confavreux,Paul O'Connor,Giancarlo Comi,Mark S. Freedman,Aaron E. Miller,Tomas Olsson,Jerry S. Wolinsky,Teresa Bagulho,Jean Luc Delhay,Deborah Dukovic,Philippe Truffinet,Ludwig Kappos +11 more
TL;DR: Teriflunomide 14 mg was associated with a lower relapse rate and less disability accumulation compared with placebo, with a similar safety and tolerability profile to that reported in previous studies.
Journal ArticleDOI
Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force
Richard A. Rudick,Jack P. Antel,Christian Confavreux,Gary Cutter,George W. Ellison,J. S. Fischer,Fred D. Lublin,Aaron E. Miller,John Petkau,Stephen M. Rao,Stephen C. Reingold,Karl Syndulko,Alan J. Thompson,Joy Wallenberg,Brian G. Weinshenker,Ernest Willoughby +15 more
TL;DR: This article provides recommendations from the National Multiple Sclerosis Society's Clinical Outcomes Assessment Task Force, which proposed a new measurement approach based on quantitative functional composites that consist of simple quantitative measures from the major clinical dimensions of MS combined into a single score.